Cost Effectiveness Analysis of a Randomized Control Trial of q3h vs. q4h

Status Withdrawn

Clinical Trial Summary

Asthma is the most common chronic condition among children, and the third leading reason for hospitalization of children in the United States. It exerts a large healthcare burden on the US with estimated annual direct healthcare cost of approximately $50.1 billion with indirect costs of $5.9 billion. Asthma is characterized by airway inflammation and airway constriction. Albuterol and other betaagonists are first line standard of care for acute exacerbations and provide short acting smooth muscle relaxation and subsequent airway opening. The frequency of albuterol administration is dependent on the severity of the exacerbation. For hospitalized patients here at Children's Memorial Hermann (CMHH), patients may receive nebulized albuterol continuously or if the exacerbation is not as severe, receive albuterol intermittently. Intermittent albuterol frequency ranges from every two hour treatments, every three hour (q3h) treatments, or every four hour (q4h) treatments. As patients recover from their acute exacerbation, their frequency of albuterol administration is progressively titrated along this continuum. Expert consensus uses q4h albuterol as discharge criteria from the hospital. However, recent QI initiatives have studied the effect of q3h treatments as the discharge cutoff with no reported changes in safety or harm. There are no randomized controlled trials available. Furthermore, there are no economic evaluations available to see if costs saved by decreasing the length of hospital care are merely being shifted to subsequent clinic or emergency room care costs. The investigators aim to conduct a randomized control trial to compare q3h vs. q4h albuterol as hospital discharge criteria for patients admitted for acute asthma exacerbations. The investigators also propose to conduct a costeffectiveness analysis of the trial. If the hypothesis that q3h albuterol is safe and as effective as q4h albuterol as discharge criteria, the investigators would be able to argue for a new standard of care that is more cost effective for this very costly and common disease of children in the United States

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04542005
Study type	Interventional
Source	The University of Texas Health Science Center, Houston
Contact
Status	Withdrawn
Phase	N/A
Start date	December 2020
Completion date	July 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04450108` - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients	N/A
Recruiting	`NCT05734261` - Forced Oscillations Technique During a Metacholine Test in Children	N/A
Recruiting	`NCT06044051` - Dynamics of the Upper and Lower Airway Respiratory Microbiomes Associated With Severe Infant Asthma	N/A
Completed	`NCT04896502` - Effectiveness of Telemedicine Home Assessments for Identification and Reduction of Asthma Triggers	N/A
Completed	`NCT03503812` - Mitigating the Health Effects of Desert Dust Storms Using Exposure-Reduction Approaches	N/A
Recruiting	`NCT06003569` - Reducing Asthma Attacks in Disadvantaged School Children With Asthma	N/A
Not yet recruiting	`NCT05902702` - Isotonic Saline for Children With Bronchiolitis	N/A
Not yet recruiting	`NCT05547477` - Continuous EMG Measurements in Children With Asthma During Sleep
Completed	`NCT04388098` - Oral Health Status of Asthmatic Children
Terminated	`NCT03586544` - Reducing Exercise-induced Bronchoconstriction in Children With Asthma and Obesity	Phase 4
Recruiting	`NCT04821908` - Consequences of COVID 19 Pandemic on Childhood Asthma
Not yet recruiting	`NCT03277170` - Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations	Phase 2
Enrolling by invitation	`NCT06239844` - Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English	N/A
Not yet recruiting	`NCT05997784` - Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
Not yet recruiting	`NCT05974917` - Serious gaMes as Emerging E-health Interventions for Young People With neurologicaL or rEspiratory disoRders
Recruiting	`NCT05366309` - Performance and Adherence in Children Using Spacers	N/A
Completed	`NCT05684926` - COVID-19 Pandemic Asthma Child Telerehabilitation Yoga	N/A
Recruiting	`NCT04166344` - A mHealth Intervention to Improve Symptom Control in Children and Adolescents With Difficult-to-control Asthma	N/A
Completed	`NCT03907410` - The Tailored Adherence Incentives for Childhood Asthma Medications (TAICAM) Trial	N/A
Completed	`NCT05576142` - Oral Findings in Pediatric Patients With Allergic Rhinitis and/or Asthma

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cost Effectiveness Analysis of a Randomized Control Trial of q3h vs. q4h Albuterol as Discharge Criteria From the Hospital for Pediatric Asthma Exacerbations

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms